Gastro-Oesophageal Reflux Symptoms - Clinical Findings and Effect of Ranitidine Treatment
| Autor: | S Hultén, B. Hallerbäck, L J Knapstad, B. Johansson, L Carling, H. Glise, A R Rosseland |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors Randomization Adolescent medicine.medical_treatment Ranitidine Placebo Gastroenterology law.invention Placebos Double-Blind Method Randomized controlled trial Recurrence law Internal medicine Humans Medicine Chemotherapy business.industry Esophageal disease Reflux Infant Middle Aged Anti-Ulcer Agents medicine.disease Surgery Clinical trial Treatment Outcome Patient Satisfaction Gastroesophageal Reflux Female business Algorithms Follow-Up Studies medicine.drug |
| Zdroj: | European Journal of Surgery. 164:6-13 |
| ISSN: | 1102-4151 |
| Popis: | Background This study was performed to study the demography, effect of treatment with ranitidine and relapse pattern in patients with reflux symptoms. Methods Patients with reflux symptoms were examined by endoscopy and included in a double-blind, comparative trial of placebo and ranitidine 150 mg b.i.d. for two weeks. At two weeks satisfied patients continued the same treatment. Non-satisfied patients were randomised to ranitidine 150 mg b.i.d. or q.i.d for another two weeks. After four weeks medication was stopped and satisfied patients were followed for 24 weeks. No further endoscopy was performed. Results Four hundred and twenty-seven patients were randomised. At two weeks there was no significant difference between placebo and ranitidine, regarding the proportion of patients with complete relief from symptoms or satisfied with treatment. Ranitidine was superior to placebo in improving symptoms at two weeks. Ranitidine, 150 mg q.i.d. offered no additional advantage in weeks three to four over prolonging treatment with 150 mg b.i.d. after the first two weeks. Patients with oesophagitis at inclusion relapsed more than those with symptoms only, 67% compared with 52%, (p = 0.013). Conclusions The effect of ranitidine was marginal compared to placebo. The relapse rate was high after treatment stopped. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text